The Limits of Genetic Medicine: Reach, Complexity, and Cost

Gene therapy has long occupied a privileged position in the biomedical imagination. The prospect of correcting disease at its genetic root, repairing faulty code rather than treating downstream symptoms, has been framed as the ultimate form of precision medicine. Over the past three decades, advances in viral vectors, genome editing technologies such as CRISPR–Cas9, and regulatory approvals for several gene therapies have appeared to validate this vision. Yet alongside these successes has emerged a growing body of critique questioning whether gene therapy, as currently conceived and pursued, represents a scalable or sustainable future for medicine.

By situating gene therapy within the broader contexts of genetic complexity, epigenetics, environmental exposure, and health systems science, its clear that although gene therapy will remain valuable for niche indications, its promise as a dominant medical paradigm may be overstated.

Population Reach and Health Impact

Despite high visibility and substantial investment, gene therapies currently benefit a remarkably small patient population. Approved gene therapies overwhelmingly target rare monogenic disorders such as spinal muscular atrophy, inherited retinal dystrophies, and certain immunodeficiencies, each affecting hundreds to thousands of patients globally rather than millions [1][2]. Even optimistic projections suggest that, at scale, gene therapies will address only a fraction of total disease burden.

In contrast, the greatest contributors to morbidity and mortality worldwide, cardiovascular disease, type 2 diabetes, cancer, chronic respiratory disease, and neurodegeneration, are multifactorial conditions driven by complex interactions among genetics, environment, and behaviour [3]. Public health interventions targeting smoking cessation, diet, physical activity, air quality, vaccination, and early screening have repeatedly demonstrated orders-of-magnitude greater population-level impact than any single biomedical innovation [4].

From a utilitarian health perspective, the opportunity cost is stark. Resources devoted to treating hundreds of patients with ultra-expensive gene therapies may yield less aggregate benefit than investments in prevention or systems-level reform that modestly improve outcomes for millions. This disparity raises legitimate questions about the strategic prioritisation of gene therapy within constrained health budgets.

Economic Sustainability and Drug Pricing

The economic model underpinning gene therapy development presents profound challenges. Research and development costs are high, driven by bespoke vector design, extensive preclinical safety testing, and small, geographically dispersed trial populations [5]. Manufacturing adds further complexity: viral vector production requires specialised facilities, rigorous quality control, and limited batch scalability, all of which constrain supply and inflate costs [6].

These factors contribute to unprecedented drug prices. Several approved gene therapies are priced between USD 1–3 million per patient, justified by manufacturers as “one-time cures” offsetting lifetime treatment costs [7]. However, real-world durability data remain limited, and long-term efficacy is uncertain in many cases [8]. Payers face significant reimbursement challenges, including budget impact, uncertainty over long-term benefit, and difficulties implementing outcome-based payment models.

From an equity standpoint, such pricing risks exacerbating global health disparities. Even in high-income countries, access is tightly rationed; in low- and middle-income settings, gene therapies are effectively inaccessible. A medical paradigm that delivers transformative benefit to very few at extraordinary cost raises concerns about sustainability and social legitimacy.

Genetic Complexity

A central assumption of gene therapy is that correcting a causal genetic defect will meaningfully alter disease trajectory. While this holds for certain monogenic disorders, most common diseases exhibit polygenic architectures involving hundreds or thousands of variants, each contributing small effects [9]. Genome-wide association studies have repeatedly shown that disease risk is distributed across networks of interacting loci rather than driven by single dominant mutations [10].

In such contexts, correcting one or two genes is unlikely to produce predictable or durable benefit. Biological systems exhibit redundancy, compensation, and nonlinear dynamics; altering one component may be buffered, bypassed, or even produce unintended effects [11]. Moreover, pleiotropy, where a single gene influences multiple traits, raises the risk that targeted correction may have unforeseen consequences elsewhere in your physiology.

These realities challenge the translational logic of gene therapy for complex disease and suggest diminishing returns as therapeutic targets move away from clearly defined monogenic pathologies.

Limits of Gene-Centric Disease Models

Recent advances in genomics have further complicated gene-centric conceptions of disease. Only approximately 1–2% of the human genome encodes protein, while much of the remainder consists of non-coding regions with regulatory, structural, or as-yet-unclear functions [12]. Although some non-coding elements play critical roles, distinguishing disease-relevant signals from background variation remains extremely difficult.

Large-scale sequencing studies have revealed extensive genetic variation among healthy individuals, undermining simplistic notions of ‘normal’ versus ‘pathological’ genomes [13]. Many variants previously thought to be deleterious are now recognised as context-dependent or benign. This ambiguity complicates target identification and increases the risk of over-interpreting genetic associations. There is still much to learn.

As a result, confidence in selecting gene targets that will translate reliably into clinical benefit is often lower than implied by gene-therapy rhetoric. The complexity of genomic regulation resists reduction to simple corrective interventions.

Epigenetics and the Exposome

Beyond DNA sequence, gene expression is dynamically shaped by epigenetic mechanisms, environmental exposures, and life-course experiences. Epigenetic modifications such as DNA methylation and histone modification regulate gene activity in response to nutrition, stress, toxins, and social context, often with long-lasting effects [14].

The concept of the exposome—the cumulative environmental exposures experienced across the lifespan—has gained increasing recognition as a major determinant of health and disease [15]. Air pollution, endocrine disruptors, diet, infection, socioeconomic stress, and early childhood adversity can all modify disease risk independently of genetic sequence.

Crucially, these influences can modulate whether and how genetic variants are expressed. Static genetic correction does not address the upstream drivers that shape phenotypic outcomes. In many cases, modifying environment, behaviour, or social conditions may yield greater benefit than altering DNA that is only contingently pathogenic.

Cost and Alternative Priorities

The pursuit of gene therapies entails significant opportunity cost. Capital, talent, regulatory attention, and political will devoted to development, resources not simultaneously available for other interventions. Systems-based innovations, such as improving primary care access, integrating digital health tools, addressing social determinants of health, and strengthening prevention infrastructures, often struggle for funding despite strong evidence of impact [4][16]. They are not perceived as ‘sexy.’

From a policy perspective, prioritising ultra-high-cost therapies for rare conditions has the potential to distort incentives within biomedical research, favouring technological novelty over population benefit. I know that when I was trying to get funding for research into diabetes and cardiovascular disease in the 1990s emphasis from granting bodies was being placed on gene research. To what end? While innovation should not be judged solely on its false starts or immediate reach, strategic balance is essential to ensure that medical progress aligns with societal needs.

Conclusion

Gene therapies represent one of the most intellectually elegant and technically impressive achievements of modern biomedical science. For certain rare monogenic disorders, they have delivered genuine, life-altering benefit and should continue to be developed and supported. We at Niche have played our own role in these initiatives and to dismiss these successes would be both inaccurate and unjust [17].

However, the broader promise of gene therapy as a dominant paradigm for future medicine warrants sceptical scrutiny. Limited population reach, extreme costs, genetic and biological complexity, and the powerful influence of epigenetic and environmental factors all constrain the transformative potential of gene-centric approaches. There is the opportunity that gene therapies do not necessarily need to reinstate 100% function. Even a 10 or 20% return of functionality can have life changing impact. However, when viewed alongside the substantial opportunity costs involved, the case for gene therapy as a primary engine of medical progress weakens.

A more balanced strategy would position gene therapy as a specialised tool within a diversified portfolio of interventions, while redirecting greater emphasis toward prevention, systems-level innovation, and the social and environmental determinants of health. In doing so, medicine may achieve not only technical brilliance, but also broader and more equitable impact.

References

1. High KA, Roncarolo MG. Gene therapy. N Engl J Med. 2019;381(5):455-64.
2. Dunbar CE, et al. Gene therapy comes of age. Science. 2018;359(6372):eaan4672.
3. Murray CJL, Lopez AD. Global mortality, disability, and the contribution of risk factors. Lancet. 2013;382(9904):2197-223.
4. Frieden TR. A framework for public health action. Am J Public Health. 2010;100(4):590-5.
5. Smith BK, Collins SW, Conlon TJ, et al. Phase I/II trial of gene therapy for muscular dystrophy. Mol Ther. 2017;25(9):2035-42.
6. Wright JF. Manufacturing challenges of gene therapy. Hum Gene Ther. 2021;32(9-10):469-76.
7. ICER. Managing the Challenges of Paying for Gene Therapy: Strategies for Market Action and Policy Reform; 2024.
8. Gupta S, et al. Long-term outcomes after gene therapy. Nat Rev Drug Discov. 2022;21(5):333-4.
9. Boyle EA, Li YI, Pritchard JK. An expanded view of complex traits. Cell. 2017;169(7):1177-86.
10. Visscher PM, et al. 10 years of GWAS discovery. Am J Hum Genet. 2017;101(1):5-22.
11. Kitano H. Biological robustness. Nat Rev Genet. 2004;5(11):826-37.
12. ENCODE Project Consortium. An integrated encyclopedia of DNA elements. Nature. 2012;489(7414):57-74.
13. Lek M, et al. Analysis of protein-coding genetic variation. Nature. 2016;536(7616):285-91.
14. Feil R, Fraga MF. Epigenetics and the environment. Nat Rev Genet. 2012;13(2):97-109.
15. Wild CP. The exposome: from concept to utility, International Journal of Epidemiology, Vol 41, 2012, 24–32.
16. Marmot M, Allen JJ. Social determinants of health equity. Am J Public Health. 2014 Sep;104 Suppl 4(Suppl 4):S517-9.
17. Cook J (2026). The Rise of Personalised Gene Therapy: a 30-year perspective.